Ono Pharmaceutical Co., Ltd.
4528.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥487 | ¥503 | ¥447 | ¥361 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Cost of Goods Sold | ¥148 | ¥127 | ¥110 | ¥94 |
| Gross Profit | ¥339 | ¥376 | ¥337 | ¥268 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| R&D Expenses | ¥150 | ¥112 | ¥95 | ¥76 |
| G&A Expenses | ¥92 | ¥73 | ¥69 | ¥63 |
| SG&A Expenses | ¥122 | ¥97 | ¥87 | ¥74 |
| Sales & Mktg Exp. | ¥31 | ¥24 | ¥18 | ¥11 |
| Other Operating Expenses | ¥7 | ¥3 | ¥13 | ¥3 |
| Operating Expenses | ¥279 | ¥212 | ¥195 | ¥153 |
| Operating Income | ¥60 | ¥163 | ¥142 | ¥115 |
| % Margin | 12.3% | 32.4% | 31.7% | 31.8% |
| Other Income/Exp. Net | -¥0 | ¥1 | ¥2 | -¥10 |
| Pre-Tax Income | ¥59 | ¥164 | ¥144 | ¥105 |
| Tax Expense | ¥9 | ¥36 | ¥31 | ¥24 |
| Net Income | ¥50 | ¥128 | ¥113 | ¥81 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS | 106.55 | 266.57 | 230.85 | 162.19 |
| % Growth | -60% | 15.5% | 42.3% | – |
| EPS Diluted | 106.41 | 266.6 | 230.79 | 162.16 |
| Weighted Avg Shares Out | 0 | 0 | 1 | 1 |
| Weighted Avg Shares Out Dil | 0 | 0 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥5 | ¥4 | ¥2 | ¥3 |
| Interest Expense | ¥5 | ¥0 | ¥1 | ¥1 |
| Depreciation & Amortization | ¥27 | ¥18 | ¥17 | ¥18 |
| EBITDA | ¥92 | ¥182 | ¥162 | ¥123 |
| % Margin | 18.8% | 36.2% | 36.2% | 34% |